ArticleRMD open2018

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.

Filip Van den Bosch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.